Loading
companiesCompany
Otsuka Pharmaceutical
Otsuka is a Japanese pharmaceutical group whose oncology portfolio centres on haematology: intravenous busulfan (Busulfex) and decitabine (Dacogen).
Also called: Astex PharmaceuticalsGraceway Pharmaceuticals, LLCGraceway Pharmaceuticals
Overview
Otsuka Pharmaceutical, part of Otsuka Holdings, is best known for CNS medicines but markets Busulfex (busulfan) for transplant conditioning and Dacogen (decitabine) for myelodysplastic syndromes in the US, and Dacogen for elderly acute myeloid leukaemia in Europe through Janssen. It also develops Lonsurf outside Japan with Taiho, a group company.
Headquarters
Tokyo, JP
Scorecard
All companies#75of 1244 companies, score 59
- approved products +18
- modalities +4
- regions +7
- registry trials +30
3 approved, 0 in phase 3, 0 earlier, 0 targets, 1,079 registry studies. Formula on the scorecards page.
Type
Large pharma · 4578.T
Stage
Public
Website
ApprovedAlkylating agent (alkyl sulfonate)
Busulfan · Myleran / Busulfex
Busulfan is one of the oldest cancer drugs. As a tablet it controlled chronic myeloid leukaemia before imatinib; as an infusion it is used to clear the bone marrow before a stem cell transplant.
ApprovedHypomethylating agent (DNA methyltransferase inhibitor)
Decitabine · Dacogen
Decitabine (Dacogen) is an infusion that loosens the chemical silencing of genes in myelodysplastic syndromes and acute myeloid leukaemia, helping the bone marrow work again. An oral version combined with cedazuridine has its own record.
ApprovedCytotoxic chemotherapy (oral nucleoside)
Trifluridine/tipiracil · Lonsurf
An oral chemotherapy pill for bowel cancer that has stopped responding to everything else; with bevacizumab it extends life by about three months.
Similar pages
- TargetDNMT1 (DNA methyltransferase 1)
Shares Decitabine, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- TrialRECOURSE
Shares Taiho Pharmaceutical (Otsuka), Trifluridine/tipiracil.
- TrialClinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Shares Decitabine, Acute myeloid leukaemia.
- TrialStudy Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT
Shares Busulfan, Acute myeloid leukaemia.
- TargetDNA methyltransferase 3A (DNMT3A)
Shares Decitabine, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- TrialASCERTAIN-V
Shares Taiho Pharmaceutical (Otsuka), Acute myeloid leukaemia.
- TrialClinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)
Shares Busulfan, Acute myeloid leukaemia.
- TrialGalinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Shares Decitabine, Acute myeloid leukaemia.
cancers
drugs
ApprovedAlkylating agent (alkyl sulfonate)
Busulfan · Myleran / Busulfex
ApprovedHypomethylating agent (DNA methyltransferase inhibitor)
Decitabine · Dacogen
ApprovedCytotoxic chemotherapy (oral nucleoside)
Trifluridine/tipiracil · Lonsurf
companies
trials
A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/LymphomaA Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic LeukemiaThe Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation